CUDA Yanqi Lake Conference | Professor Xiaodong Wen : From Evidence to Practice — How Real-World Precision Therapy Addresses Clinical Challenges in Urologic Oncology

CUDA Yanqi Lake Conference | Professor Xiaodong Wen : From Evidence to Practice — How Real-World Precision Therapy Addresses Clinical Challenges in Urologic Oncology

Randomized controlled trials (RCTs), regarded as the “gold standard” of evidence-based medicine, serve as the cornerstone for establishing oncology treatment guidelines. However, it is equally important to recognize that the strict inclusion and exclusion criteria of RCTs often create a significant gap between trial populations and the realities of everyday clinical practice, where many patients are elderly, have multiple comorbidities, or have experienced failure of several prior treatment lines.
“Deep Dive Debate” | After Achieving pCR with Immunotherapy in TNBC, Should Adjuvant Immunotherapy Be Continued or Stopped?

“Deep Dive Debate” | After Achieving pCR with Immunotherapy in TNBC, Should Adjuvant Immunotherapy Be Continued or Stopped?

With the success of landmark clinical studies such as KEYNOTE-522, neoadjuvant treatment for early-stage triple-negative breast cancer (TNBC) has fully entered the era of immunotherapy combined with chemotherapy. While this strategy has significantly improved pathological complete response (pCR) rates and delivered substantial survival benefits, it has also raised one of the most debated questions in current clinical practice:
2026 CSCO BC Guideline Highlights | Professor Jiayi Chen: Key Updates in Breast Cancer Radiotherapy

2026 CSCO BC Guideline Highlights | Professor Jiayi Chen: Key Updates in Breast Cancer Radiotherapy

The 2026 National Breast Cancer Conference was held in Beijing from April 10–12, during which major updates to the Chinese Society of Clinical Oncology (CSCO) Breast Cancer Guidelines 2026 (CSCO BC Guidelines 2026) were officially released. At the meeting, Professor Jiayi Chen from Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, reviewed and interpreted the latest updates in the radiotherapy section of the guidelines.
2026 CSCO BC Guideline Highlights | Professor Chunfang Hao: Key Updates in Salvage Endocrine Therapy for HR-Positive Advanced Breast Cancer — Multi-Directional Strategies, Precision Assessment, Optimized Combinations, and Sequential Multi-Target Therapy

2026 CSCO BC Guideline Highlights | Professor Chunfang Hao: Key Updates in Salvage Endocrine Therapy for HR-Positive Advanced Breast Cancer — Multi-Directional Strategies, Precision Assessment, Optimized Combinations, and Sequential Multi-Target Therapy

The 2026 National Breast Cancer Conference was held in Beijing from April 10–12, during which the Chinese Society of Clinical Oncology (CSCO) Breast Cancer Guidelines 2026 (CSCO BC Guidelines 2026) underwent major updates. At the meeting, Professor Chunfang Hao from Tianjin Medical University Cancer Institute and Hospital delivered a comprehensive overview of the latest advances in the management of HR-positive breast cancer.
2026 CSCO BC Guideline Highlights | Professor Kun Wang: Key Updates in Neoadjuvant and Adjuvant Management of HER2-Positive Early Breast Cancer

2026 CSCO BC Guideline Highlights | Professor Kun Wang: Key Updates in Neoadjuvant and Adjuvant Management of HER2-Positive Early Breast Cancer

The 2026 National Breast Cancer Conference was held in Beijing from April 10–12, during which important updates to the Chinese Society of Clinical Oncology (CSCO) Breast Cancer Guidelines 2026 (CSCO BC Guidelines 2026) were officially released. At the meeting, Professor Kun Wang from Guangdong Provincial People’s Hospital presented and interpreted the latest updates in neoadjuvant and adjuvant treatment strategies for early breast cancer.
2026 CSCO Guidelines Conference | Academician Jinming Yu: Strengthening China-Based Evidence, Advancing Global Guideline Outreach, and Bringing Standardized Cancer Care to the Grassroots Level

2026 CSCO Guidelines Conference | Academician Jinming Yu: Strengthening China-Based Evidence, Advancing Global Guideline Outreach, and Bringing Standardized Cancer Care to the Grassroots Level

The 2026 Chinese Society of Clinical Oncology (CSCO) Guidelines Conference was grandly held in Harbin from April 24–25. Bringing together more than a thousand experts, the meeting focused on guideline updates, intelligent healthcare, and multidisciplinary collaboration, with a strong emphasis on extending standardized cancer care to grassroots medical institutions and narrowing regional disparities in oncology practice.
2026 HOT Conference | Professor Zhenzhen Liu: From Live Surgical Demonstrations to Specialty Center Development — Advancing Breast Cancer Care on Multiple Fronts

2026 HOT Conference | Professor Zhenzhen Liu: From Live Surgical Demonstrations to Specialty Center Development — Advancing Breast Cancer Care on Multiple Fronts

With the warmth of spring invigorating the Central Plains, the 18th Northern Breast Cancer HOT Conference was successfully held in Zhengzhou from April 16–18, 2026. During the meeting, Oncology Frontier conducted an exclusive interview with the conference chair, Professor Zhenzhen Liu from Henan Cancer Hospital. In the interview, she discussed the conference’s major highlights, the development of specialty center models, and both the challenges and practical value of promoting multidisciplinary team (MDT) care at the grassroots level.
CSCO BC 10th Anniversary Tribute | Professor Zefei Jiang: A Decade of Progress — CSCO BC Leading China’s Breast Cancer Field Toward a New Global Era

CSCO BC 10th Anniversary Tribute | Professor Zefei Jiang: A Decade of Progress — CSCO BC Leading China’s Breast Cancer Field Toward a New Global Era

Along the long journey of breast cancer prevention and treatment, the successful convening of the 2026 National Breast Cancer Conference stands as a shining milestone. Even more significant is the 10th anniversary of the Breast Cancer Committee of the Chinese Society of Clinical Oncology (CSCO BC). Over the past decade, CSCO BC has grown from its inception into a major driving force in China’s breast cancer field, achieving remarkable progress in clinical research, guideline development, promotion of standardized care, and international academic collaboration.
CSCO BC 10th Anniversary Tribute | Professor Yongmei Yin: A New Starting Point, A New Mission — CSCO BC Leading China’s Breast Cancer Care into a New Era of High-Quality Development

CSCO BC 10th Anniversary Tribute | Professor Yongmei Yin: A New Starting Point, A New Mission — CSCO BC Leading China’s Breast Cancer Care into a New Era of High-Quality Development

As the Breast Cancer Committee of the Chinese Society of Clinical Oncology (CSCO BC) marks its 10th anniversary, the 2026 National Breast Cancer Conference was grandly convened. More than an academic gathering, this conference served as a comprehensive review of CSCO BC’s decade-long journey and a blueprint for the future of breast cancer care in China.